Rozlytrek
FDA Expands Pediatric Indication for Rozlytrek and Approves New Pellet Formulation
The FDA granted accelerated approval to entrectinib (Rozlytrek, Genentech) for pediatric patients older than 1 ...
OCTOBER 24, 2023
FDA Approves Rozlytrek for NTRK Solid Tumors and ROS1 NSCLC
The FDA granted accelerated approval to Rozlytrek for patients aged 12 years and older with solid tumors that have ...
AUGUST 19, 2019
Load more